115 related articles for article (PubMed ID: 11111818)
1. Immunoadsorption for the treatment of rheumatoid arthritis: final results of a randomized trial. Prosorba Trial Investigators.
Furst D; Felson D; Thoren G; Gendreau RM
Ther Apher; 2000 Oct; 4(5):363-73. PubMed ID: 11111818
[TBL] [Abstract][Full Text] [Related]
2. The Prosorba column for treatment of refractory rheumatoid arthritis: a randomized, double-blind, sham-controlled trial.
Felson DT; LaValley MP; Baldassare AR; Block JA; Caldwell JR; Cannon GW; Deal C; Evans S; Fleischmann R; Gendreau RM; Harris ER; Matteson EL; Roth SH; Schumacher HR; Weisman MH; Furst DE
Arthritis Rheum; 1999 Oct; 42(10):2153-9. PubMed ID: 10524687
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis.
Gendreau RM;
Ther Apher; 2001 Apr; 5(2):79-83. PubMed ID: 11354303
[TBL] [Abstract][Full Text] [Related]
4. Effects of Prosorba column apheresis in patients with chronic refractory rheumatoid arthritis.
Roth S
J Rheumatol; 2004 Nov; 31(11):2131-5. PubMed ID: 15517623
[TBL] [Abstract][Full Text] [Related]
5. Vasculitis secondary to staphylococcal Protein A immunoadsorption (Prosorba column) treatment in rheumatoid arthritis.
Deodhar A; Allen E; Daoud K; Wahba I
Semin Arthritis Rheum; 2002 Aug; 32(1):3-9. PubMed ID: 12219317
[TBL] [Abstract][Full Text] [Related]
6. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
7. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.
Strand V; Cohen S; Schiff M; Weaver A; Fleischmann R; Cannon G; Fox R; Moreland L; Olsen N; Furst D; Caldwell J; Kaine J; Sharp J; Hurley F; Loew-Friedrich I
Arch Intern Med; 1999 Nov; 159(21):2542-50. PubMed ID: 10573044
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
Ogrendik M
Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration.
Anderson JJ; Wells G; Verhoeven AC; Felson DT
Arthritis Rheum; 2000 Jan; 43(1):22-9. PubMed ID: 10643696
[TBL] [Abstract][Full Text] [Related]
11. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.
Song YW; Lee EY; Koh EM; Cha HS; Yoo B; Lee CK; Baek HJ; Kim HA; Suh Y; Kang SW; Lee YJ; Jung HG
Clin Ther; 2007 May; 29(5):862-873. PubMed ID: 17697905
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin binding properties of the Prosorba immunadsorption column in treatment of rheumatoid arthritis.
Sasso EH; Merrill C; Furst TE
Ther Apher; 2001 Apr; 5(2):84-91. PubMed ID: 11354304
[TBL] [Abstract][Full Text] [Related]
15. A pilot study using a staph protein A column (Prosorba) to treat refractory rheumatoid arthritis.
Caldwell J; Gendreau RM; Furst D; Wiesenhutter C; Quagliata F; Spindler J; Bertram J
J Rheumatol; 1999 Aug; 26(8):1657-62. PubMed ID: 10451058
[TBL] [Abstract][Full Text] [Related]
16. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
[TBL] [Abstract][Full Text] [Related]
17. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
18. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
Lü LJ; Teng JL; Bao CD; Han XH; Sun LY; Xu JH; Li XF; Wu HX
Chin Med J (Engl); 2008 Apr; 121(7):615-9. PubMed ID: 18466681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
